Nasdaq warns Cardima over listing requirements
This article was originally published in Clinica
Cardima's ailing fortunes could soon spell a delisting from the US stock exchange. The Fremont, California-based company has received written notice from Nasdaq that, following a review of its third-quarter results for the period ended September 30 2004 and of its listed securities' market value, the firm had fallen below the minimum requirements to remain eligible for listing on the market.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.